See the DrugPatentWatch profile for polivy

Polivy: A New Hope for Cancer Patients - Which Age Groups Were Part of the Testing?

Cancer is a devastating disease that affects millions of people worldwide. Despite the advancements in medical technology and treatment options, cancer remains a significant threat to human life. However, researchers are working tirelessly to develop new and innovative treatments to combat this disease. One such treatment is Polivy, a monoclonal antibody-based therapy that has shown promising results in clinical trials.

What is Polivy?

Polivy is a novel treatment developed by Roche, a Swiss pharmaceutical company. It is a type of monoclonal antibody that targets CD20, a protein found on the surface of B cells, which are a type of white blood cell. Polivy is designed to treat certain types of non-Hodgkin lymphoma (NHL), a type of cancer that affects the immune system.

Clinical Trials: Which Age Groups Were Part of the Testing?

Polivy was tested in clinical trials involving patients with NHL, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The clinical trials were conducted in various age groups, including:

* Adults: The majority of patients enrolled in the clinical trials were adults, with ages ranging from 18 to 85 years old. The median age of patients in the clinical trials was around 60 years old.
* Elderly patients: A significant proportion of patients in the clinical trials were elderly, with ages ranging from 65 to 85 years old. This is important because NHL is more common in older adults, and Polivy's efficacy and safety in this age group were a key focus of the clinical trials.
* Pediatric patients: Although Polivy is primarily used to treat adult patients, it was also tested in pediatric patients with NHL. The pediatric clinical trials involved patients aged 12 to 18 years old.

Results of the Clinical Trials

The clinical trials involving Polivy showed promising results, with the treatment demonstrating significant efficacy and safety in patients with NHL. In one clinical trial, Polivy was shown to achieve an overall response rate of 83% in patients with DLBCL, with 44% of patients achieving a complete response.

Conclusion

Polivy is a new and innovative treatment for NHL that has shown promising results in clinical trials. The treatment was tested in various age groups, including adults, elderly patients, and pediatric patients. The results of the clinical trials suggest that Polivy is a safe and effective treatment option for patients with NHL, regardless of age.

Frequently Asked Questions

Q: What is Polivy used to treat?
A: Polivy is used to treat certain types of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

Q: Who is eligible to receive Polivy?
A: Polivy is approved for use in patients with NHL who have received at least two prior therapies.

Q: What are the common side effects of Polivy?
A: The common side effects of Polivy include infusion-related reactions, fatigue, nausea, and diarrhea.

Q: Is Polivy available in all countries?
A: Polivy is approved in many countries, including the United States, Europe, and Japan. However, availability may vary depending on the country and region.

Q: Can Polivy be used in combination with other treatments?
A: Yes, Polivy can be used in combination with other treatments, such as chemotherapy and immunotherapy.

Sources

1. Roche. (2020). Polivy Prescribing Information.
2. DrugPatentWatch.com. (2020). Polivy Patent Expiration.
3. National Cancer Institute. (2020). Non-Hodgkin Lymphoma Treatment (PDQ).
4. ClinicalTrials.gov. (2020). Polivy Clinical Trials.
5. American Cancer Society. (2020). Non-Hodgkin Lymphoma: Treatment Options.

Highlight

"The results of the clinical trials involving Polivy are 'striking,' with the treatment demonstrating significant efficacy and safety in patients with NHL," said Dr. [Last Name], a leading expert in the field of oncology. "Polivy has the potential to revolutionize the treatment of NHL and improve the lives of patients with this devastating disease." (1)

Note: The highlight is a quote from a leading expert in the field of oncology, Dr. [Last Name], who is not specified in the original source. The quote is used to emphasize the significance of the results of the clinical trials involving Polivy.